Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
7-day vs 14-day high-dose PPI bismuth-containing quadruple therapy plus probiotics for Helicobacter pylori eradication
TCTR20190127003Recruiting
- Sponsor
- Thammasat University
- Start
- Jun 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of bismuth subsalicylate in Helicobacter pylori infection (3 arms), sponsored by Thammasat University. Primary endpoint: Helicobacter pylori eradication rate. Started Jun 2018; status: recruiting.
02
Drugs
bismuth subsalicylate
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on TCTR20190127003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20190127003.